ML169  (Synonyms: VU0405652)

ML169 (VU0405652) is a potent, selective and brain penetrant positive allosteric modulator (PAM) of M₁ mAChR, with an EC₅₀ of 1.38 µM. ML169 is a MLPCN probe and can be used for Alzheimer’s disease^[1].

EC₅₀: 1.38 µM (M1 mAChR)^[1]

ML169 (VU0405652) is selective versus the biogenic amines (D2, H-HT2B, etc...) and displays no orthosteric binding at M₁–M₅^[1].
ML169 shifts APP processing towards a non-amyloidogenic pathway^[1].
ML169 (2 µM) potentiates the carbachol (CCh)-mediated non-amyloidogenic APPsa release to the same degree as 10 µM CCh^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

ML169 (VU0405652) (10 mg/kg; i.p.) affords a brain_AUC/plasma_AUC of 0.32 at 1 h in rats^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

506.34

C₂₁H₁₇BrFN₃O₄S

1222878-02-5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Reid PR, et al. Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe. Bioorg Med Chem Lett. 2011 May 1;21(9):2697-701.  [Content Brief]